BiotechTube

Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide

Phase 2Active
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ewing Sarcoma

Conditions

Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma

Trial Timeline

May 24, 2019 → Oct 18, 2025

NCT ID
NCT03709680

About Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide

Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide is a phase 2 stage product being developed by Pfizer for Ewing Sarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT03709680. Target conditions include Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03709680Phase 2Active

Competing Products

14 competing products in Ewing Sarcoma

See all competitors
ProductCompanyStageHype Score
LinsitinibAstellas PharmaPhase 2
52
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
52
Abemaciclib + Irinotecan + TemozolomideEli LillyPhase 2
52
IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)Eli LillyPhase 2
52
XaluritamigAmgenPhase 1
32
CP-751,871PfizerPhase 1
32
CP-751,871PfizerPhase 1/2
40
plerixafor + plerixafor + plerixaforSanofiPhase 1/2
40
regorafenib tabletBayerPhase 1
30
INCB059872IncytePhase 1
30
LurbinectedinJazz PharmaceuticalsPhase 1/2
38
LurbinectedinJazz PharmaceuticalsPhase 1/2
38
CabozantinibExelixisPhase 1
30
INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + FluorouracilInhibrx BiosciencesPhase 1
28

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84